Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
|Articles|September 14, 2015
Evolving Paradigms
- Squamous NSCLC
- Volume 1
- Issue 1
Evolving Paradigms in Squamous NSCLC: Conclusion
Author(s)Staff Writer
Squamous cell lung cancer represents a distinct molecular pathologic NSCLC with unmet therapeutic needs, especially after failure of first-line platinum-based doublet chemotherapy.
Advertisement
This article is Part III of a series. View parts I and II:Evolving Paradigms in Squamous NSCLC> >
Articles in this issue
about 11 years ago
Cancer Immunotherapy: Evolving Treatment Options in Squamous NSCLCabout 11 years ago
Evolving Paradigms in Squamous NSCLC: Referencesabout 11 years ago
Evolving Paradigms in Squamous NSCLC: IntroductionAdvertisement
Related to this article
SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; the gap narrowed at age 80 and older.
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU use, and similar disease control.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5